Mapi Pharma Doses First PPMS Patient in Phase 2 Trial Evaluating GA Depot

The Phase 2a trial of GA Depot (glatiramer acetate) for the treatment of primary progressive multiple sclerosis (PPMS) has dosed the first patient, Mapi Pharma recently announced.

In the U.S., Copaxone (glatiramer acetate injection, marketed by Teva Pharmaceutical) is the standard therapy for relapsing-remitting multiple sclerosis (RRMS), which is the most prevalent type of the disease.

GA Depot, Israel-based Mapi’s lead product, also contains glatiramer acetate and is a long-acting depot formulation injection given once every four weeks, compared to Copaxone’s more frequent daily or three times a week dosage.

PPMS is characterized by a gradual deterioration of neurologic function starting with the onset of symptoms, without early relapses or remissions. The prospective, multicenter Phase 2a trial (NCT03362294) will address GA Depot’s safety and efficacy in slowing the progression of disability in PPMS patients.

The study will be open label, which means that both investigators and participants know what drug is being administered, and that no placebo control is used.